Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9001106 | 0.84 | MAPT (0.30) | MAPTCACNA1BAPBA1 | |
| SCHEMBL28836695 | 0.80 | — | — | |
| SCHEMBL6438119 | 0.79 | NPSR1 (0.32) | — | |
| SCHEMBL7737385 | 0.79 | — | — | |
| SCHEMBL8521945 | 0.78 | ALDH1A1 (0.31) | MAPTALDH1A1TSHR | |
| SCHEMBL8694565 | 0.77 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL2155070 | 0.77 | TSHR (0.41) | ALDH1A1TSHR | |
| SCHEMBL9766294 | 0.76 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL250246 | 0.76 | TSHR (0.30) | MAPTTSHR | |
| SCHEMBL250244 | 0.76 | TSHR (0.30) | MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724278-B1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | claimed |
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | claimed |
| JP-9066673-A | — | — | None | — | — | JP | disclosed |
| US-20050176797-A1 | 2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1408963-A1 | 2- 5-(5-CARBAMIMIDOYL-1 i H /i -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030114457-A1 | 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | US | disclosed |
| WO-2003006011-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| US-6281240-B1 | CYSTIC FIBROSIS | ELI LILLY AND COMPANY | 2001-08-28 | — | — | US | disclosed |
| EP-0972797-A1 | RUBBER COMPOSITION CONTAINING METAL SALT OF ETHYLENICALLY UNSATURATED CARBOXYLIC ACID | NIPPON ZEON CO., LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998044799-A1 | DIARYLSULFONYLUREAS FOR USE IN TREATING SECRETORY DIARRHEA | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5668176-A | ENDOTHELIN ANTAGONIST | MERCK & CO. INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5030270-A | Sulfonylureas with heterocyclic substituents, and the use thereof as herbicides or plant-growth regulators | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-07-09 | — | — | US | disclosed |
| US-4906288-A | Herbicidal pyridyl sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0117014-B1 | HERBICIDAL N-HYDROXY-N'-SULFONYLGUANIDINES AND SULFONAMIDE INNER SALTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4723991-A | Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| EP-0125864-B1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-04-08 | — | — | EP | disclosed |
| US-4604133-A | Herbicidal sulfonamide inner salts | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| US-4484939-A | PRE-AND POST-EMERGENCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-11-27 | — | — | US | disclosed |
| EP-0125864-A1 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-11-21 | — | — | EP | disclosed |
| EP-0117014-A1 | Herbicidal N-hydroxy-N'-sulfonylguanidines and sulfonamide inner salts | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114457-A1 | 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | F7, F9, F5 | MAPT 4637/4885CACNA1B 1589/4885APBA1 1476/4885 |
| US-20050176797-A1 | 2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors | F7, F9, F5 | MAPT 4637/4885CACNA1B 1589/4885APBA1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.